Journal

Journal of Basic and Clinical Physiology and Pharmacology

Editor-in-Chief: Ugo Oliviero
Managing Editor: Alberto Marra

Language: English

First published: December 1, 1986

View latest issue

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

About this journal

Objective
The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including Emergency Medicine, Oncology, Hematology and Coagulation disorders, Vascular Medicine, Gastroenterology, Liver Disease, Neurology and Cerebrovascular Diseases, Gender Medicine, Endocrinology, Diabetology and Metabolism, Cardiovascular Diseases, Heart Failure, Respiratory Disease, Geriatrics, Immunology and Rheumatology.

Moreover, Manuscripts regarding basic and laboratory sciences will be very welcome.

As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes.　

Topics

Emergency Medicine
Oncology
Hematology and Coagulation disorders
Vascular Medicine
Gastroenterology
Liver Disease
Neurology and Cerebrovascular Diseases
Gender Medicine
Endocrinology
Diabetology and Metabolism
Cardiovascular Diseases
Heart Failure
Respiratory Disease
Geriatrics
Immunology
Rheumatology

Article formats
Research Articles, Reviews and Mini Reviews, Short Communications, Editorials and Letters to the Editor

Your Benefits

State-of-the-art research in physiology and pharmacology
Integrative approach to descriptive and behavioral studies
Leading-edge techniques
High quality peer-review

Complete Archive Access

As of 2026, all De Gruyter journal subscriptions include access to every issue, from Volume 1, Issue 1 through to today, meaning subscribers can access even more research at no additional cost.

Requires Authentication Unlicensed
Licensed

Serum copper, rubidium, selenium, strontium, and zinc and psychophysical health in adults of the Sarno river Basin: PREVES-STOP 2025 community biomonitoring results

January 5, 2026

Luca Scafuri, Raffaele Baio, Carlo Buonerba, Felice Crocetto, Antonio Verde, Antonella Ferraioli, Vittorio Riccio, Serena Rizzano, Sara Rizzano, Armando Pisapia, Vittorino Montanaro, Emily Ronga, Giuseppe Romeo, Antonio Ruffo, Matteo Ferro, Mauro Iuliano, Marco Trifuoggi, Alessandra Marano, Gaetano De Tommaso, Flavia Conte, Rossella Di Trolio, Oriana Strianese, Alessia Vitolo, Luigia Maglione, Paola Tarantino, Francesco Stanzione, Francesca Cappuccio, Ferdinando Costabile, Giuseppe Di Lorenzo

Download PDF

Objectives Evaluate associations between serum copper (Cu), rubidium (Rb), selenium (Se), strontium (Sr), and zinc (Zn) and psychophysical health in adults from Italy’s Sarno River Basin within the 2025 PREVES-STOP program. Methods Adults aged 30–65 completed validated questionnaires plus clinical evaluation and blood sampling. Elements were quantified by collision/reaction-cell inductively coupled plasma mass spectrometry (ICP-MS). Associations were evaluated using Spearman and partial Spearman correlations. Results Significant associations included Zn and Rb associated with lower odds (odds ratio, OR) of severe fatigue – Recognizing and Estimating Signs of Tiredness (REST): Zn OR=0.38, 95 % confidence interval (CI) 0.21–0.68, q=0.02; Rb OR=0.33, 95 % CI 0.15–0.71, q=0.03 – while Sr was associated with higher well-being – the World Health Organization-5 Well-Being Index (WHO-5) OR=1.36, 95 % CI 1.12–1.65, q=0.02. Conclusions Findings support broader trace-element panels to inform psychophysical and cardiometabolic risk beyond classical toxic metals, complementing prior PREVES-STOP evidence on lead (Pb) and cadmium (Cd). Further investigation is warranted.
Requires Authentication Unlicensed
Licensed

Prediction of risk factors and electrocardiographic changes in chronic kidney disease patients

February 3, 2026

Sanjaya Kumar Panigrahi, Madhuchhanda Pattnaik, Aruna Acharya

Download PDF

Objectives Chronic kidney disease (CKD) is a global health issue with significant morbidity and mortality, particularly due to cardiovascular events. Early identification and management of risk factors are crucial to prevent CKD progression and complications. CKD is heterogeneous with diverse etiologies and presentations, generalizing across populations challenging. This study aims to develop accurate predictive models for cardiovascular events in CKD patients. Methods Biosensors capture key parameters, including SpO 2 (Oxygen saturation), PR (Pulse rate), Pi (Perfusion index), RRp (Respiration rate), and PVi (Pleth variability index), enabling comprehensive evaluation of physiological dynamics in CKD patients. Stacked Auto-Encoders (SAEs) are applied for diagnostics. Genetic risk score (GRS) and nongenetic risk score (NGRS) models are developed using natural logarithms of odds ratios (OR) of risk factors. Results The models integrate properties of each factor with weighted contributions to create predictive models for CKD. A novel machine learning technique incorporates automatic machine learning (AutoML). Conclusions The models integrate properties of each factor with weighted contributions to create predictive models for CKD. A novel machine learning technique incorporates automatic machine learning (AutoML).
Requires Authentication Unlicensed
Licensed

The transformative role of GLP-1 receptor agonists in obesity and chronic disease: clinical insights from a dialogue with artificial intelligence

January 8, 2026

Rahi Gandhi

Download PDF
Requires Authentication Unlicensed
Licensed

Contrast-induced acute kidney injury: from pathophysiology to risk prediction and prevention strategies

February 3, 2026

Pooja Anjanappa, Sunita Kularia, Yogendra Shrestha

Download PDF

Concerns regarding contrast-induced acute kidney injury (CI-AKI) remain significant due to the increasing use of iodinated contrast agents (ICM) in diagnostic and medical procedures. Although the frequency of CI-AKI has decreased over the decades, it continues to be a major cause of hospital-acquired acute kidney damage, thereby elevating the risk of mortality, morbidity, and prolonged hospital stays. The complex pathophysiology of CI-AKI involves vasoconstriction, oxidative stress, renal medullary hypoxia, inflammatory responses, and direct tubular toxicity. Recent discoveries have identified ferroptosis and neutrophil extracellular traps (NETs) as additional mechanisms contributing to endothelial and tubular damage. Furthermore, microRNAs such as miR-30c, miR-21, and miR-141-3p have emerged as preliminary biomarkers and therapeutic targets due to their regulatory effects on cellular apoptosis and inflammatory pathways. Procedural controversies persist regarding the risk differences between intravenous and intra-arterial contrast administration; however, evidence suggests that patient comorbidities and procedural complexity, rather than the route of administration alone, determine the risk of CI-AKI. Risk stratification tools, such as the Mehran and ACEF scores, provide frameworks for identifying high-risk patients and guiding preventive strategies. This review integrates an understanding of the molecular pathogenesis of CI-AKI, clarifies procedural debates, and highlights emerging biomarkers and risk models.
Requires Authentication Unlicensed
Licensed

Echoes of a silent rupture: acute right ventricular failure due to post-ischemic ventricular septal defect in the emergency department – a case report

January 5, 2026

Mariateresa Pontoriero, Claudia Serra, Arianna Piglia, Giuseppe Ambrosio, Dimitri Garifalos, Claudio Marra, Fabio Giuliano Numis

Download PDF

Objectives Post-infarction ventricular septal defect is a rare but severe mechanical complication of acute myocardial infarction that can lead to cardiogenic shock and carries a high mortality rate. Early recognition and multidisciplinary management are essential for improving survival. Case presentation A 58-year-old previously healthy woman presented to the Emergency Department with syncope and cardiogenic shock due to an anterior myocardial infarction. Echocardiography revealed an apical ventricular septal defect with severe biventricular dysfunction and right ventricular failure, confirmed by computed tomography. Urgent coronary angiography demonstrated total occlusion of the left anterior descending artery, treated with stent implantation. Despite maximal medical therapy, she required emergency surgical repair with patch closure and concomitant coronary bypass grafting. Conclusions This case highlights the challenges of post-infarction VSD presenting with predominant right sided heart failure, requiring rapid and multidisciplinary management, including prompt surgical intervention, and advanced mechanical circulatory support.
Requires Authentication Unlicensed
Licensed

A prospective study to assess the prognosis of patients with necrotizing fasciitis using laboratory risk indicator for necrotizing fasciitis (LRINEC) scoring system in a tertiary care hospital

December 17, 2025

Rekha Walwekar, Vignesh Ramalingam, Arun Walwekar

Download PDF

Introduction Necrotizing fasciitis (NF) is a rare but potentially fatal infection, involving the subcutaneous tissue and fascia. The incidence of NF worldwide ranges from 0.30 to 15 cases per 100,000 populations and mortality remains high at 25 %. Objectives To classify severity of necrotizing fasciitis and assess the prognosis of necrotizing fasciitis using the LRINEC Scoring system. Methods A thorough history and detailed clinical examination was done. Patient underwent necessary investigations like hemoglobulin, total leukocyte count, serum sodium, serum creatinine, random blood sugar, and C-reactive protein. Based on the investigations, two groups were formulated, LRINEC score <6 (low risk) and ≥6 (high risk). Then prognosis was assessed. The results were compared between the two groups. Results In our study, a total of 124 patients were included with 62 of them with LRINEC score of <6 and 62 patients with LRINEC score ≥6. The sensitivity and specificity for predicting the septic shock and mortality with LRINEC score is 94 % and 70 % and 94 % and 71 %, respectively. Conclusions LRINEC score is a simple clinical tool for predicting the prognostic outcomes in patients with necrotizing fasciitis. LRINEC score of ≥6 have poorer prognosis in the form septic shock and eventual mortality.
Requires Authentication Unlicensed
Licensed

Early aggressive treatment with DMARDs vs. step-up therapy in rheumatoid arthritis: a traditional review of joint damage and functional outcomes

December 25, 2025

Amruth Akhil Alluri, Aditya Rajesh Pawar, Shrishti Prakash Khetan, Rohan Singhal, Shruti Suresh Suvarna, Mehal Ravindra Adsure, Swathi N.L.

Download PDF

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint inflammation and structural damage. Two primary treatment strategies – step-up therapy and early aggressive DMARD therapy have been widely debated in clinical practice. The step-up approach begins with NSAIDs or corticosteroids, progressing to DMARDs based on disease severity, whereas early aggressive therapy prioritizes immediate DMARD initiation to prevent irreversible joint damage. This comprehensive review evaluates the effectiveness of these strategies by analyzing randomized controlled trials (RCTs), meta-analyses, and cohort studies assessing treatment outcomes, remission rates, and radiographic progression. A literature search was conducted across PubMed, Scopus, and Web of Science, including studies published between 2010 and 2024. Key clinical trials, including TICORA, COBRA, BeSt, and CAMERA, were critically analyzed to assess the comparative benefits and limitations of both treatment approaches. Evidence suggests that early aggressive therapy is associated with higher remission rates, reduced radiographic progression, and improved long-term physical function, whereas the step-up approach often leads to delayed disease control and cumulative joint damage. However, concerns related to treatment adherence, cost-effectiveness, and safety profiles necessitate further investigation. Future research should focus on biomarker-driven personalized treatment strategies, optimizing drug sequencing, and long-term comparative effectiveness studies to refine RA management.
Requires Authentication Unlicensed
Licensed

Metformin modulates antioxidant and anti-inflammatory biomarkers in newly diagnosed patients with type 2 diabetes mellitus: an observational study

January 22, 2026

Saurav Misra, Tirthankar Deb, Savita Devi, Amandeep Singh, Richa Goel

Download PDF

Objectives Diabetes mellitus is a chronic metabolic condition marked by high blood sugar levels. As a primary treatment for type 2 diabetes (T2DM), metformin has demonstrated positive effects on antioxidant and anti-inflammatory biomarkers in newly diagnosed patients. Methods This was a prospective observational study. Blood samples were collected three times to analyse biomarkers. The study involved newly diagnosed T2DM patients who provided written informed consent. The assessments included plasma lipid peroxidation, superoxide dismutase (SOD), catalase, and Malondialdehyde (MDA) levels. Additionally, interleukin-6 (IL-6) was measured to evaluate inflammation. Results HbA1c levels significantly decreased at the 6-month follow-up. Analysis showed a reduction in SOD levels at each visit, with a statistically significant difference between the first and second follow-ups (p=0.03028). MDA levels also decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05). Catalase levels increased at each visit, but only between the first and second follow-ups (p=0.03124). IL-6 levels decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05). Conclusions Metformin reduces oxidative stress and inflammation in patients with type 2 diabetes, aiding in protecting cells and tissues.
Open Access
Artificial intelligence applied to achalasia: an emerging frontier in precision motility care? State of the art and future prospects

December 25, 2025

Agostino Fernicola, Domenico Parmeggiani, Felice Crocetto, Murtaja Satea Shafeea, Alessio Cece, Armando Calogero, Annunziata Gaetana Cicatiello, Giacomo Benassai, Gennaro Quarto, Michele Santangelo

Download PDF

Introduction Esophageal achalasia is a rare motility disorder characterized by impaired lower esophageal sphincter relaxation and absent peristalsis. Diagnostic tools such as high-resolution manometry (HRM) and functional lumen imaging probe (FLIP) have improved disease recognition; however, interpretation remains complex and highly operator dependent. Artificial intelligence (AI) has emerged as a promising approach to automate data analysis and enhance diagnostic accuracy, but its specific role in achalasia is not yet clearly defined. Content A narrative review was conducted using PubMed, Scopus, and Web of Science, searching for studies published up to June 2025 that investigated AI applications in esophageal motility disorders, with particular attention to achalasia. Search terms included “artificial intelligence,” “machine learning,” “achalasia,” “esophageal motility,” and “high-resolution manometry.” Although no prospective or interventional studies directly evaluating AI in achalasia were identified, several retrospective proof-of-concept studies applied AI algorithms to HRM and FLIP data. These studies demonstrated the feasibility of automated classification of esophageal motility disorders, with high accuracy in differentiating motility subtypes potentially applicable to achalasia. Exploratory research on AI-assisted imaging and outcome prediction also showed encouraging results. Summary Current evidence suggests that AI-based models can accurately analyze complex esophageal motility data and reduce interobserver variability. While direct clinical evidence in achalasia remains limited, existing studies provide a solid methodological foundation for AI-assisted diagnosis, classification, and clinical decision support in this condition. Outlook Future research should focus on prospective validation, multicenter data collection, and multimodal integration of clinical, physiologic, and imaging data. With targeted development and ethical governance, AI has the potential to enhance diagnostic precision, support personalized treatment strategies, and advance precision motility care in patients with achalasia.
Requires Authentication Unlicensed
Licensed

Efficacy of flower pollen extract with vitamins in improving urinary and sexual function in patients with chronic prostatitis: a retrospective study

December 25, 2025

Carlo Giulioni, Valentina Maurizi, Federico Falsetti, Felice Crocetto, Angelo Cafarelli

Download PDF

Objectives To assess the efficacy and safety of Flower Pollen Extract with Vitamins (PEV) in improving urinary and sexual function in men diagnosed with chronic prostatitis (CP). Methods A retrospective controlled study was conducted involving 145 men with CP. Participants were divided into two groups: the intervention group received PEV (n=71) and the control group received ibuprofen (n=74). Clinical and functional outcomes were evaluated at baseline and at 1, 3, and 12 months post-treatment. Results Both groups exhibited comparable baseline characteristics. At 3 months, the PEV group demonstrated significantly greater improvement in IPSS (9.4 ± 2.7 vs. 10.3 ± 2.6, p=0.04), NIH-CPSI (11.5 ± 3.7 vs. 13.6 ± 4.2, p=0.002), and IIEF-5 (19.8 ± 3.6 vs. 17.7 ± 3.3, p<0.001). These benefits were maintained and further enhanced at 12 months, with mean IPSS 7.6 ± 2.1, NIH-CPSI 6.5 ± 2.4, and IIEF-5 21.6 ± 3.3 in the PEV group (all p<0.005). No significant differences were observed in Qmax. Conclusions Long-term PEV therapy significantly improves urinary and sexual function in men with CP compared with ibuprofen treatment, demonstrating sustained, time-dependent efficacy and excellent safety.
Requires Authentication Unlicensed
Licensed

Efficacy and safety of Mirikizumab in the treatment of moderate to severe active ulcerative colitis: a systematic review

December 15, 2025

Ajay Kumar Shukla, Saurav Misra, Ravi Kant Narayan, Shahnawaz Ahmed

Download PDF

Introduction Ulcerative colitis in the second or third decade is characterised by haematochezia, stomach pain, faecal urgency, and tenesmus. On October 26, 2023, the US-FDA approved Mirikizumab for the treatment of moderate-to-severe ulcerative colitis in adults. Content This systematic review evaluated the safety and effectiveness of Mirikizumab for the treatment of ulcerative colitis by analysing data from available clinical trials. We performed a thorough search across databases such as PubMed, Cochrane, Embase, Scopus, Google Scholar, and ClinicalTrials.gov, covering records from their inception up to June 30, 2025, in accordance with PRISMA guidelines. Thorough investigation identified five relevant studies: four randomised controlled trials and one observational study. All Mirikizumab doses achieved complete healing of the inflamed lumen. Except for the 50 mg dose, they also showed superior histological remission compared to placebo. Most adverse effects likely stem from the condition itself rather than the drug, supported by a higher dropout rate among placebo patients. Additionally, in patients with prior treatment failures, Mirikizumab demonstrated improved outcomes by week 40. Summary and Outcome Mirikizumab improves clinical, endoscopic, and histological results in ulcerative colitis. This study highlights the clinical importance of Mirikizumab and its potential to change treatment standards for ulcerative colitis.
Requires Authentication Unlicensed
Licensed

An overview and comparison of haemovigilance reporting forms across six countries relative to the WHO template

December 11, 2025

Manmeet Kaur, Saurav Misra, Jayant Kumar Kairi

Download PDF

Objectives Haemovigilance monitors, identifies, reports, investigates, and analyses adverse event near-misses and reactions related to transfusion and blood product manufacture. Methods This was an observational study in which we analyzed and compared the WHO haemovigilance template form for hospital and blood establishment haemovigilance reporting forms from Australia, Canada, India, New Zealand, South Africa, and the United States. All data from these reporting systems/forms was tabulated. The study analyzed data elements from each form, scoring them based on their presence in the WHO template and country forms. Higher scores indicated greater comparability and more comprehensive data collection. Results We identified 57 data fields in haemovigilance reporting forms from six countries and the WHO template, essential for collecting information on suspected transfusion products and reactions. The US FDA form has the most fields at 40 (70 %), followed by Canada with 33 (58 %) and India with 27 (47 %). New Zealand’s form has the fewest at 16 (28 %), followed by South Africa with 17 (30 %). Conclusions Effective haemovigilance systems require time and commitment to develop, often starting small and growing with stakeholder involvement. A straightforward reporting form, accessible to all, is crucial for success.

CiteScore	4.2	2024, Scopus (Elsevier B.V., 2025)
SCImago Journal Rank	0.487	2024, SJR (Scimago Lab, 2025; Data Source: Scopus)
Source Normalized Impact per Paper	0.541	2024, CWTS Journal Indicators (CWTS B.V., 2025; Data Source: Scopus)

Journal of Basic and Clinical Physiology and Pharmacology

Overview

About this journal

Your Benefits

Ahead of Publication / Just Accepted

Issues

Ranking

Submit

Editorial

Abstracting and Indexing

Supplementary Materials

Supplementary Materials

Topics

Topics

External Links

Bibliographic data